These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 22131939)

  • 21. Vitamin E for neuroleptic-induced tardive dyskinesia.
    Soares KV; McGrath JJ
    Cochrane Database Syst Rev; 2001; (4):CD000209. PubMed ID: 11687073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Stress oxidative in schizophrenia].
    Tylec A; Jarzab A; Stryjecka-Zimmer M; Wójcicka A
    Pol Merkur Lekarski; 2007 Jul; 23(133):74-7. PubMed ID: 18051835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of Blood Biochemical Markers with Tardive Dyskinesia in Schizophrenic Patients.
    Wu Q; Yuan F; Zhang S; Liu W; Miao Q; Zheng X; Lu S; Hou K
    Dis Markers; 2022; 2022():1767989. PubMed ID: 35299866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acupuncture for schizophrenia.
    Shen X; Xia J; Adams CE
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005475. PubMed ID: 25330045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antioxidant and anti-inflammatory nutrient status, supplementation, and mechanisms in patients with schizophrenia.
    Mitra S; Natarajan R; Ziedonis D; Fan X
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Aug; 78():1-11. PubMed ID: 28499901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benzodiazepines for neuroleptic-induced tardive dyskinesia.
    Bhoopathi PS; Soares-Weiser K
    Cochrane Database Syst Rev; 2006 Jul; (3):CD000205. PubMed ID: 16855954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of melatonin supplementation on oxidative stress parameters: A systematic review and meta-analysis.
    Morvaridzadeh M; Sadeghi E; Agah S; Nachvak SM; Fazelian S; Moradi F; Persad E; Heshmati J
    Pharmacol Res; 2020 Nov; 161():105210. PubMed ID: 33007423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of antioxidants: scope, limitations and relevance of assays.
    Pinchuk I; Shoval H; Dotan Y; Lichtenberg D
    Chem Phys Lipids; 2012 Sep; 165(6):638-47. PubMed ID: 22721987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholinergic medication for neuroleptic-induced tardive dyskinesia.
    Tammenmaa IA; McGrath JJ; Sailas E; Soares-Weiser K
    Cochrane Database Syst Rev; 2002; (3):CD000207. PubMed ID: 12137608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxidative Stress and Emergence of Psychosis.
    Rambaud V; Marzo A; Chaumette B
    Antioxidants (Basel); 2022 Sep; 11(10):. PubMed ID: 36290593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement.
    Rodrigo R; Korantzopoulos P; Cereceda M; Asenjo R; Zamorano J; Villalabeitia E; Baeza C; Aguayo R; Castillo R; Carrasco R; Gormaz JG
    J Am Coll Cardiol; 2013 Oct; 62(16):1457-65. PubMed ID: 23916928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valproate for schizophrenia.
    Schwarz C; Volz A; Li C; Leucht S
    Cochrane Database Syst Rev; 2008 Jul; (3):CD004028. PubMed ID: 18646098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics.
    Khan MM; Evans DR; Gunna V; Scheffer RE; Parikh VV; Mahadik SP
    Schizophr Res; 2002 Nov; 58(1):1-10. PubMed ID: 12363384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review.
    Pardis P; Remington G; Panda R; Lemez M; Agid O
    J Psychopharmacol; 2019 Oct; 33(10):1187-1198. PubMed ID: 31347436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benzodiazepines for neuroleptic-induced tardive dyskinesia.
    Umbrich P; Soares KV
    Cochrane Database Syst Rev; 2003; (2):CD000205. PubMed ID: 12804389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticholinergic medication for antipsychotic-induced tardive dyskinesia.
    Bergman H; Soares-Weiser K
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD000204. PubMed ID: 29341071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia.
    Zhang XY; Tan YL; Zhou DF; Cao LY; Wu GY; Haile CN; Kosten TA; Kosten TR
    J Clin Psychiatry; 2007 May; 68(5):754-60. PubMed ID: 17503985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antioxidants for male subfertility.
    Showell MG; Mackenzie-Proctor R; Brown J; Yazdani A; Stankiewicz MT; Hart RJ
    Cochrane Database Syst Rev; 2014; (12):CD007411. PubMed ID: 25504418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
    Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
    Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders.
    Quraishi S; David A
    Cochrane Database Syst Rev; 2000; (2):CD001470. PubMed ID: 10796442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.